Treprostinil
CAS No. 81846-19-7
Treprostinil( LRX-15 | Orenitram | Remodulin )
Catalog No. M19938 CAS No. 81846-19-7
Treprostinil is a potent DP1 IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 55 | In Stock |
|
| 5MG | 65 | In Stock |
|
| 10MG | 110 | In Stock |
|
| 25MG | 234 | In Stock |
|
| 50MG | 367 | In Stock |
|
| 100MG | 551 | In Stock |
|
| 200MG | 780 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTreprostinil
-
NoteResearch use only, not for human use.
-
Brief DescriptionTreprostinil is a potent DP1 IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).
-
DescriptionTreprostinil is a potent DP1 IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).
-
In VitroTreprostinil has high affinity for the DP1, EP2 and IP receptors (Ki=4.4, 3.6 and 32 nM, respectively), low affinity for EP1 and EP4 receptors and even lower affinity for EP3, FP and TP receptors. Activation of IP, DP1 and EP2 receptors, as with treprostinil, can all result in vasodilatation of human pulmonary arteries.Treprostinil inhibits viability of cultured endothelial colony forming cells. Endothelial colony forming cells proliferation is stimulated by conditioned media from Treprostinil pretreated mesenchymal stem cells.
-
In VivoInhaled treprostinil sodium, a prostacyclin analog, is the most recent agent to receive FDA approval for the treatment of a fatal orphan disease: pulmonary arterial hypertension (PAH). Treprostinil preserves the sinusoidal endothelial cell lining and reduces platelet deposition early post-transplantation compared to placebo. Hepatic tissue blood flow is significantly compromised in the placebo group, whereas treprostinil maintains blood flow similar to normal levels.Treprostinil treatment significantly increases the vessel-forming ability of endothelial colony forming cells combined with mesenchymal stem cells in Matrigel implanted in nude mice. Silencing VEGF-A gene in mesenchymal stem cells also blocks the pro-angiogenic effect of Treprostinil. Treprostinil is most efficacious in raising intracellular cAMP levels in murine and human hematopoietic stem and progenitor cells. Treatment with Treprostinil significantly reduces the recruitment of cells compared to normoxic mice. Treprostinil also reduces right ventricular systolic pressure and slightly reduces the vascular remodelling but fails to reverse the right ventricular hypertrophy.
-
SynonymsLRX-15 | Orenitram | Remodulin
-
PathwayGPCR/G Protein
-
TargetProstaglandin Receptor
-
RecptorDP1 IP EP2
-
Research AreaCardiovascular Disease
-
IndicationPulmonary hypertension
Chemical Information
-
CAS Number81846-19-7
-
Formula Weight390.51
-
Molecular FormulaC23H34O5
-
Purity>98% (HPLC)
-
SolubilityDMSO: 40 mg/mL;Ethanol: 20 mg/mL
-
SMILESCCCCC[C@H](O)CC[C@H]1[C@H](O)C[C@@H]2Cc3c(C[C@H]12)cccc3OCC(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Whittle BJ et al. Binding and activity of the prostacyclin receptor (IP) agonists treprostinil and iloprost at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. Biochem Pharmacol. 2012 Jul 1;84(1):68-75.
molnova catalog
related products
-
Tafluprost
Tafluprost, a prostaglandin analog, is the selective agonist of fluoroprostaglandin (FP) receptor PGF2α.Tafluprost showed significant IOP-lowering effects without any safety concerns in patients with various types of glaucoma and OH in daily clinical practice and tafluprost is highly effective in any therapeutic pattern.
-
TG6-129
TG6-129 is an antagonist of the EP2 receptor. TG6-129 suppresses PGE2-induced elevation of cAMP in cells expressing EP2 with an IC50 value of 1.6 μM.
-
BGC201531
BGC201531 is a EP4 antagonist for the treatment of acute migraine.
Cart
sales@molnova.com